Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
RATIONALE: Studying samples of cells in the laboratory from patients with cancer may help
 identify biomarkers related to cancer. It may also help doctors learn how patients respond to
 treatment.

 PURPOSE: This laboratory study is analyzing samples of cells from patients with chronic
 lymphocytic leukemia who were treated on clinical trial ECOG-2997.
OBJECTIVES:

 -  To analyze the expression of a variety of informative molecules using a unique
 high-resolution flow cytometric immunophenotyping technology in samples from patients
 with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.

 OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70,
 phospho-Syk, phospho-GSK-3β, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1,
 phospho-ReIA, IkappaBα, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker
 signals are amplified using enzymatic amplification staining to obtain high resolution
 detection of cell-surface markers on leukemic cells. Biomarker expression levels are measured
 using fluorescence activated cell sorting analysis. Relationships between clinical outcomes,
 standard flow cytometric analysis, cytogenetic studies, and high resolution immunophenotyping
 will also be assessed.
DISEASE CHARACTERISTICS:

 -  Stored frozen viable cells from patients with chronic lymphocytic leukemia treated on
 clinical trial ECOG-2997

 PATIENT CHARACTERISTICS:

 -  Not specified

 PRIOR CONCURRENT THERAPY:

 -  Not specified